NCT07234422RecruitingPhase 3
The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
A Registry-Based Randomised Controlled Trial With Heart 4 Data - SELEnium and CoQ10 NuTrition for Heart Failure: H4D-SELEQT-HF
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Participants will: Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment Attend standard clinical visits according to routine clinical care. The study will include 1,100 adults with chronic heart failure. Selenium and CoQ10 are natural nutrients with no known health risks. If effective, this supplement could provide a safe new way to improve outcomes for people with heart failure.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1100 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 4 May 2026
- Primary completion date
- Dec 2030
- Lead sponsor
- Netherlands Heart Institute
- Diseases
- Heart failure
- NCT number
- NCT07234422
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1100
- From 4 May 2026 to the primary completion date, Dec 2030
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of myocardial infarction, myocarditis, percutaneous intervention, cardiac surgery or stroke \<30 days
- Scheduled for mechanical assist device or heart transplant
- Other non-cardiac conditions with limited life expectancy (\<1 year)
- End stage kidney disease for which chronic intermittent peritoneal or haemodialysis
- Peanut and/or soy allergy
Other
- The presence of a mechanical assist device
- Amyloid, hypertrophic obstructive or constrictive cardiomyopathy
- Unable to sign informed consent
- (Unwilling to stop) use of over the counter supplements coQ10/selenium
Who the study is looking for
- Age \>18 years
- Outpatients with chronic HF, NYHA II - ambulatory IV
- Serum NT-proBNP concentrations \>600 pg/mL (71 pmol/L) if in sinus rhythm; \>1000pg/mL (118 pmol/L) if in Atrial fibrillation\*
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Noordwest Ziekenhuisgroep Coordinator of this site? Confirm its status | Alkmaar | Netherlands | Not yet recruiting |
| AUMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Not yet recruiting |
| Amphia Ziekenhuis Coordinator of this site? Confirm its status | Breda | Netherlands | Recruiting |
| Catharina Ziekenhuis Eindhoven Coordinator of this site? Confirm its status | Eindhoven | Netherlands | Not yet recruiting |
| Treant Coordinator of this site? Confirm its status | Emmen | Netherlands | Not yet recruiting |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
| St. Antonius Ziekenhuis Coordinator of this site? Confirm its status | Nieuwegein | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.